Literature DB >> 22172512

Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT.

Guillaume Mabilleau1, Florence Pascaretti-Grizon, Michel Félix Baslé, Daniel Chappard.   

Abstract

Rheumatoid arthritis (RA) is associated with pathological bone destruction mediated by osteoclasts. Although RANKL has been reported as a crucial factor for osteoclastogenesis, several other factors increased in RA support osteoclast formation and resorption in the absence of RANKL such as TNF-alpha and LIGHT. To date, in vitro bone resorption experiments are reported as the mean area of bone resorption per cortical or dentine slices and do not provide any information about depth and volume of resorption. The aims of this study were to assess these parameters by light microscopy and vertical scanning profilometry (VSP). Peripheral blood mononuclear cells were used as a source of osteoclast precursors and were cultured for up to 21 days in the presence of RANKL, TNF-alpha/IL-1 or LIGHT. Mean area, depth and volume of resorption were assessed by light microscopy and vertical scanning profilometry. As expected, RANKL induced large resorption pits (10,876 ± 2190μm(2)) whereas TNF-alpha/IL-1 and LIGHT generated smaller pits (respectively 1328 ± 210 and 1267 ± 173μm(2)) with no noticeable differences between these two cytokines. Depth and volume of resorption measured by VSP showed that RANKL promoted deep resorption pits resulting in large volume of resorption. Interestingly, although mean area of resorption was similar between TNF-alpha/IL-1 and LIGHT, the depth and volume of resorption of these lacunae were significantly increased by 2-fold with TNF-alpha/IL-1. These results provide evidence that although LIGHT appeared elevated in the synovial fluid of RA patients, its role in bone resorption is less than TNF-alpha/IL-1 or RANKL.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172512     DOI: 10.1016/j.cyto.2011.11.014

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

Review 1.  Pathways for bone loss in inflammatory disease.

Authors:  Tobias Braun; Georg Schett
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

Review 2.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

Review 3.  Osteoclasts-Key Players in Skeletal Health and Disease.

Authors:  Deborah Veis Novack; Gabriel Mbalaviele
Journal:  Microbiol Spectr       Date:  2016-06

4.  Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

Authors:  M C van der Goes; J W G Jacobs; M S Jurgens; M F Bakker; M J van der Veen; J H van der Werf; P M J Welsing; J W J Bijlsma
Journal:  Osteoporos Int       Date:  2012-08-02       Impact factor: 4.507

Review 5.  The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects.

Authors:  Marlies C van der Goes; Johannes W Jacobs; Johannes W Bijlsma
Journal:  Arthritis Res Ther       Date:  2014-11-13       Impact factor: 5.156

6.  Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis.

Authors:  Afsie Sabokbar; Sara Afrough; David J Mahoney; Yoshinobu Uchihara; Catherine Swales; Nicholas A Athanasou
Journal:  World J Exp Med       Date:  2017-05-20

7.  Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis.

Authors:  Lauren A Jordan; Malin C Erlandsson; Benjamin F Fenner; Ruth Davies; Ann K Harvey; Ernest H Choy; Rachel Errington; Maria I Bokarewa; Anwen S Williams
Journal:  Rheumatology (Oxford)       Date:  2018-11-01       Impact factor: 7.580

8.  Mediators of inflammation-induced bone damage in arthritis and their control by herbal products.

Authors:  Siddaraju M Nanjundaiah; Brian Astry; Kamal D Moudgil
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-07       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.